How do you approach systemic therapy for locoregional recurrence in a patient with triple negative breast cancer who has previously received anthracycline and taxane based chemotherapy?

The CALOR trial took a pragmatic approach and randomized patients to systemic therapy or not. A specific regimen wasn't specified. If the patient has a known BRCA mutation, I would extrapolate from the first line metastatic setting and use a single agent platinum. Outside of that unique situation, there is really no data to support special/unique sensitivity for platinums. The trial closest to this situation would be the CreateX trial (residual disease after neoadjuvant therapy). Based on those ...